CD274 and cancer: One study (NCT03228667) is currently exploring the therapeutic benefit of five different mAbs targeting PD-1 or PD-L1 in combination with PD-L1-directed CAR NK cells in cancer patients who have relapsed from treatment with immune checkpoint inhibitors.